Bromday, Bromsite, Prolensa, Xibrom, Yellox (bromfenac) is a small molecule pharmaceutical. Bromfenac was first approved as Bromday on 2005-03-24. It is used to treat eye pain, inflammation, and postoperative pain in the USA. It has been approved in Europe to treat ophthalmologic surgical procedures and postoperative pain. The pharmaceutical is active against prostaglandin G/H synthase 1. In addition, it is known to target DNA polymerase III subunit beta. Prolensa's patents are valid until 2033-11-11 (FDA).
|Indication||eye pain, inflammation, ophthalmologic surgical procedures, postoperative pain|
|Drug Class||Anti-inflammatory agents (acetic acid derivatives)|